RESUMEN
COVID-19 is a rapidly spreading disease, posing a huge hazard to global health. The plasmid vaccine pTK1A-TPA-SpikeA (named COVID-eVax) encodes the severe acute respiratory syndrome coronavirus 2 S protein receptor-binding domain, developed for intramuscular injection followed by electroporation (EP). The aim of this study was to assess the systemic toxicity and local tolerance of COVID-eVax delivered intramuscularly followed by EP in Sprague Dawley (SD) rats. The animals were killed 2 days and 4 weeks after the last injection (30-day and 57-day, respectively). No mortality was observed, and no signs of toxicity were evident, including injection site reactions. A lasting and specific immune response was observed in all treated animals, confirming the relevance of the rat as a toxicological model for this vaccine. Histopathological evaluation revealed muscle fiber necrosis associated with subchronic inflammation at the injection sites (at the 30-day time point), with a clear trend for recovery at the 57-day time point, which is expected following EP, and considered a desirable effect to mount the immune response against the target antigen. In conclusion, the intramuscular EP-assisted DNA vaccine, COVID-eVax showed an excellent safety profile in SD rats under these experimental conditions and supports its further development for use in humans.
Asunto(s)
COVID-19 , Vacunas de ADN , Animales , Anticuerpos Antivirales , Vacunas contra la COVID-19 , Electroporación , Humanos , Plásmidos , Ratas , Ratas Sprague-Dawley , SARS-CoV-2 , Vacunas de ADN/toxicidadRESUMEN
Callithrix jacchus (common marmoset) is one of the more primitive non-human primate species and is used widely in fundamental biology, pharmacology and toxicology studies. Marmosets breed well in captivity with good reproductive efficiencies and their sexual maturity is reached within 18 months of age allowing for rapid expansion of colonies and early availability of sexually mature animals permitting an earlier assessment of product candidates in the adult. Their relatively small size allows a reduction in material requirements leading to a reduction in development time and cost. Fewer animals are also required due to their ability to be used in both pharmacology and toxicology (nonclinical) studies. These factors, alongside a better understanding of their optimal nutrient and welfare requirements over recent years, facilitate the generation of a more cohesive and robust dataset. With the growth of biotechnology-derived pharmaceuticals, non-human primate use has, by necessity, also increased; nevertheless, there is also a growing public call for minimizing their use. Utilizing, the more primitive marmoset species may provide the optimal compromise and once the scientific rationale has been carefully considered and their use justified, there are several advantages to using the marmoset as a model in nonclinical development of pharmaceutical products.
Asunto(s)
Callithrix/fisiología , Preparaciones Farmacéuticas , Farmacocinética , Pruebas de Toxicidad , Crianza de Animales Domésticos , Animales , Tamaño Corporal , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Femenino , Masculino , Modelos Animales , Preparaciones Farmacéuticas/química , Preparaciones Farmacéuticas/metabolismo , Reproducibilidad de los Resultados , Especificidad de la EspecieRESUMEN
OBJECTIVES: In the present work, a method to induce experimental allergic encephalomyelitis (EAE) in female SJL/J mice was developed and validated in our laboratory. Although the latter is a popular animal model to mimic human multiple sclerosis, it remains to be clarified if: (1) the measurement of circulating antibodies against myelin antigens can be used as an index to predict the development of clinical EAE, as well as the severity of disease, and (2) the genetic susceptibility of this strain is associated with altered hypothalamo-pituitary-adrenal (HPA) function. METHODS AND RESULTS: We observed that SJL/J mice display a strong humoral response to immunization with myelin basic protein (MBP), as assessed by the titration of circulating anti-MBP antibodies. However, there was no apparent correlation between the presence and amount of circulating antibodies and the occurrence or severity of disease. Concerning the responsiveness of the HPA axis, we observed that circulating corticosterone levels are not modified at all during the induction of EAE, whereas an increase is observed at a later stage of the disease. CONCLUSIONS: The above profile is strongly reminiscent of the HPA axis response to the induction of EAE in Lewis rats, suggesting that the susceptibility of SJL/J mice to EAE may similarly be caused, at least in part, by blunted HPA reactivity to immune challenges.